Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Jan 29, 2020	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0001193125-20-018606.pdf 0001193125-20-018606.rtf 0001193125-20-018606.xls View HTML
Feb 14, 2020	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0001172661-20-000907.pdf 0001172661-20-000907.rtf 0001172661-20-000907.xls View HTML
Jan 11, 2021	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0000902219-21-000009.pdf 0000902219-21-000009.rtf 0000902219-21-000009.xls View HTML
Feb 02, 2021	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0000834237-21-006800.pdf 0000834237-21-006800.rtf View HTML
Mar 04, 2022	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0001214659-22-003638.pdf 0001214659-22-003638.rtf 0001214659-22-003638.xls View HTML
Jul 08, 2022	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0000834237-22-010307.pdf 0000834237-22-010307.rtf View HTML
Sep 01, 2022	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0001461790-22-000022.pdf 0001461790-22-000022.rtf 0001461790-22-000022.xls View HTML
Mar 04, 2019	Filing by person(s) reporting owned shares of common stock in a public company >5%	SC 13D	Other	0001193125-19-062378.pdf 0001193125-19-062378.rtf 0001193125-19-062378.xls View HTML
Jun 01, 2023	Post-effective amendment to an S-8 filing	S-8 POS	Registration Statements	0001104659-23-067090.pdf 0001104659-23-067090.rtf View HTML
Jun 01, 2023	Post-effective amendment to an S-8 filing	S-8 POS	Registration Statements	0001104659-23-067092.pdf 0001104659-23-067092.rtf View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.